Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J Viallet
Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition With U0126, Rapamycin and BCL-2 Inhibitor GX15-070
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Related publications
Targeting Glycolysis in Leukemia: A Novel Inhibitor 3-BrOP in Combination With Rapamycin
Leukemia Research
Cancer Research
Oncology
Hematology
Discovery and Characterization of a Novel Potent Type II Native and Mutant BCR-ABL Inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
Oncotarget
Oncology
BCL-2 Phosphorylation Modulates Sensitivity to the BH3 Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction With Bortezomib in Chronic Lymphocytic Leukemia Cells
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Deletion of 14-3-3σ Sensitizes Mice to DMBA/TPA-induced Papillomatosis
Oncotarget
Oncology
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571
Clinical Cancer Research
Cancer Research
Oncology
The Chimeric Ubiquitin Ligase SH2-U-box Inhibits the Growth of Imatinib-Sensitive and Resistant CML by Targeting the Native and T315i-Mutant BCR-ABL
Scientific Reports
Multidisciplinary
Simultaneous Targeting of Aurora Kinases and BCR-Abl Kinase by the Small Molecule Inhibitor PHA-739358 Is Effective Against Imatinib-Resistant BCR-ABL Mutations Including T315I
Blood
Biochemistry
Immunology
Cell Biology
Hematology
A Type-Ii Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of BCR-Abl
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML
Molecular Pharmaceutics
Drug Discovery
Molecular Medicine
Pharmaceutical Science
